Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This trial was open to participants who had received a liver transplant or had cirrhosis due
to chronic HCV. All subjects were treated with daclatasvir+sofosbuvir+ribavirin and were
followed for 24 weeks post treatment. Under certain conditions, the treatment duration could
have been extended for cirrhotic participants. The study tested the efficacy and safety of
this combination for treatment of HCV in cirrhotic and post transplant patients.